Given that combination therapy is required to optimize the efficacy, TTI-622 is the preferred SIRPα fusion protein to proceed in phase 1b/2 testing for patients with AML, including TP53m-AML. This evidence concerns the gene SIRPA and acute myeloid leukemia.